Insider Selling: Chemed (NYSE:CHE) CEO Sells $1,002,800.00 in Stock

Chemed Corporation (NYSE:CHE) CEO Kevin Mcnamara sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $501.40, for a total value of $1,002,800.00. Following the completion of the sale, the chief executive officer directly owned 68,418 shares of the company’s stock, valued at $34,304,785.20. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Chemed Trading Up 0.4%

Shares of CHE stock opened at $498.64 on Thursday. The business’s fifty day moving average price is $523.36 and its 200 day moving average price is $457.58. The firm has a market capitalization of $6.52 billion, a PE ratio of 25.04, a P/E/G ratio of 2.00 and a beta of 0.51. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.89. Chemed Corporation has a 1-year low of $365.20 and a 1-year high of $557.00.

Chemed (NYSE:CHE) last released its earnings results on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, beating analysts’ consensus estimates of $5.60 by $0.46. The company had revenue of $673.25 million during the quarter, compared to the consensus estimate of $665.04 million. Chemed had a return on equity of 31.77% and a net margin of 10.60%.Chemed’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the company earned $4.27 earnings per share. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. As a group, sell-side analysts forecast that Chemed Corporation will post 23.55 EPS for the current fiscal year.

Chemed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Monday, August 17th were given a dividend of $0.70 per share. The ex-dividend date was Monday, August 17th. This is an increase from Chemed’s previous quarterly dividend of $0.60. This represents a $2.80 annualized dividend and a yield of 0.6%. Chemed’s dividend payout ratio (DPR) is currently 14.06%.

Analysts Set New Price Targets

CHE has been the topic of several research analyst reports. Oppenheimer boosted their price target on Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Weiss Ratings raised Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 17th. Royal Bank Of Canada lifted their price objective on Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Wall Street Zen lowered Chemed from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 19th. Finally, Bank of America reiterated a “neutral” rating on shares of Chemed in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $530.75.

Institutional Investors Weigh In On Chemed

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in shares of Chemed in the second quarter valued at $691,290,000. TD Asset Management Inc lifted its holdings in Chemed by 7.5% in the 4th quarter. TD Asset Management Inc now owns 324,546 shares of the company’s stock valued at $138,860,000 after purchasing an additional 22,715 shares in the last quarter. Epoch Investment Partners Inc. boosted its stake in shares of Chemed by 4.9% during the 4th quarter. Epoch Investment Partners Inc. now owns 322,408 shares of the company’s stock worth $137,945,000 after purchasing an additional 15,133 shares during the last quarter. First Trust Advisors LP boosted its stake in shares of Chemed by 24.7% during the 1st quarter. First Trust Advisors LP now owns 236,392 shares of the company’s stock worth $89,295,000 after purchasing an additional 46,791 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Chemed during the fourth quarter worth about $76,067,000. Institutional investors and hedge funds own 95.85% of the company’s stock.

About Chemed

Chemed Corporation is a diversified holding company that operates businesses in the healthcare and residential and commercial services industries. Its primary operations are conducted through VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services are delivered in patients’ homes, hospice residences, nursing facilities, hospitals and other care settings, primarily throughout the United States. Care is provided by interdisciplinary teams that may include physicians, nurses, hospice aides, social workers and chaplains.

Roto-Rooter provides plumbing and drain-cleaning services, as well as water cleanup and related services for residential and commercial customers.